• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, November 17, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Dendrobium Polysaccharide Restores Intestinal Barrier in Mice

by
November 10, 2026
in Agriculture, Health
Reading Time: 6 mins read
0
Dendrobium Polysaccharide Restores Intestinal Barrier in Mice

Dendrobium Polysaccharide Restores Intestinal Barrier in Mice

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Researchers have reported that a specific polysaccharide extracted from the orchid Dendrobium chrysotoxum can help prevent and treat inflammatory bowel disease in mice. The study, published in the journal Food, Nutrition and Health, demonstrates that the compound, designated as Dendrobium chrysotoxum polysaccharide or DCP, improves the integrity of the intestinal barrier and modulates the gut microbiome. The findings suggest that DCP may serve as a natural intervention for managing IBD. The team led by Wenzhen Liao and colleagues utilized a mouse model to investigate the mechanisms behind these effects, focusing on tight junction proteins and short-chain fatty acid production.

Inflammatory bowel disease is a significant global health issue, with two primary clinical forms: Crohn’s disease and ulcerative colitis. The condition is driven by the breakdown of the intestinal barrier and an imbalance in the intestinal flora. According to data from the Chinese Center for Disease Control and Prevention, the number of IBD patients in China was approximately 350,000 between 2005 and 2014, with projections indicating a rise to 1.5 million by 2025. Current drug therapies for IBD are often unsatisfactory, with some patients failing to respond to treatment. This has increased interest in natural dietary substances that might prevent or alleviate the disease.

The study employed male C57BL/6 mice to establish an IBD model using Dextran Sodium Sulfate, or DSS. The mice were divided into five groups: a normal control group, a model group treated with DSS, and three groups receiving low, medium, or high doses of DCP alongside DSS. The DCP was administered intragastrically for seven days, followed by a seven-day modeling cycle with DSS in the drinking water. This experimental design allowed the researchers to assess the preventive and therapeutic potential of the polysaccharide at different dosage levels.

One of the primary mechanisms investigated was the expression of tight junction proteins, which are critical for maintaining the mechanical barrier of the intestine. The researchers used real-time fluorescence quantitative PCR and Western blotting to measure the levels of claudin-2, occludin, and ZO-1 in the colon tissue. In the DSS-treated model group, the expression of these proteins was significantly decreased compared to the control group, indicating impaired barrier function. However, intervention with DCP, particularly at the medium dose, restored the expression of these tight junction proteins, suggesting that DCP protects the integrity of the intestinal mucosa.

The study also examined the anti-inflammatory effects of DCP by measuring the expression of the cytokine IL-10. IL-10 is an anti-inflammatory factor. The results showed that IL-10 expression was significantly down-regulated in the model group. After DCP intervention, the expression of IL-10 increased significantly in all DCP-treated groups, with a dose-dependent trend. This indicates that DCP may alleviate intestinal inflammation by enhancing the production of anti-inflammatory cytokines. The medium dose was found to be the most effective, while the high dose showed a less pronounced effect, possibly due to competitive inhibition.

To understand the impact of DCP on the gut microbiome, the researchers performed 16S rRNA gene sequencing on cecal contents. The analysis revealed that DSS treatment altered the diversity and composition of the intestinal flora. Specifically, the Shannon and Simpson indices, which measure alpha diversity, were lower in the model group compared to the control group. DCP intervention did not significantly affect alpha diversity but did alter the beta diversity, as shown by Principal Coordinate Analysis. The microbial community structure in the DCP medium-dose group was more similar to that of the control group than to the model group.

At the genus level, the study found that DSS treatment increased the relative abundance of Bacteroides and Muribaculum while decreasing Desulfovibrio. DCP intervention reversed these changes, decreasing Bacteroides and Muribaculum and increasing Desulfovibrio. At the phylum level, the model group showed a decrease in Firmicutes and Actinobacteria and an increase in Bacteroidetes and Proteobacteria. DCP treatment restored the relative abundances of these phyla, bringing them closer to the levels observed in the control group. These shifts in microbial composition suggest that DCP helps restore a healthier gut microbiome in IBD mice.

The study also investigated the production of short-chain fatty acids, or SCFAs, which are metabolites produced by bacterial fermentation and play a role in maintaining intestinal homeostasis. The researchers quantified acetic acid, propionic acid, butyric acid, valeric acid, and isobutyric acid in fecal samples. DSS treatment led to a decrease in the levels of these SCFAs. DCP intervention significantly increased the level of acetic acid and increased the levels of the other SCFAs, although not all changes were statistically significant. The restoration of SCFA levels suggests that DCP may improve the metabolic function of the gut microbiota.

The findings of this study provide evidence that DCP can improve intestinal barrier dysfunction and modulate the gut microbiome in mice with IBD. The medium dose of DCP was identified as the optimal intervention, suggesting a potential therapeutic window for the compound. The study highlights the importance of the intestinal barrier and gut microbiota in the pathogenesis of IBD and offers a new perspective on the use of natural polysaccharides for disease management.

However, the study has limitations. It was conducted in mice, and the results may not directly translate to human patients. The authors note that more in-depth and comprehensive studies are required to fully understand the mechanisms of action and to evaluate the potential of DCP as a treatment for IBD.

This research contributes to the growing body of evidence supporting the use of natural compounds in the management of inflammatory bowel disease. By identifying DCP as a potential intervention, the study opens new avenues for research into the therapeutic applications of Dendrobium species. The findings underscore the complex interplay between the intestinal barrier, gut microbiota, and inflammatory responses in IBD, and highlight the potential of targeting these pathways for disease prevention and treatment.

The study was published in the journal Food, Nutrition and Health in January 2026, identifying the research as an original investigation into the biological activity of the newly extracted polysaccharide. The authors, including Mengting Wu, Zijun Xia, and Wenzhen Liao, noted that while previous studies have shown that Dendrobium officinale polysaccharide can interact with intestinal epithelial cells and exhibit anti-inflammatory activity in colitis models, there was no prior literature reporting on the specific effects of Dendrobium chrysotoxum polysaccharide on inflammatory bowel disease. This gap in the literature motivated the current investigation, which aimed to determine whether DCP could improve the biological activity associated with IBD. The research team emphasized that DCP is a natural plant active substance with advantages of safety, wide source, and low cost, making it a candidate for further exploration in the context of IBD management.

In the experimental design, the researchers selected male C57BL/6 mice aged five to six weeks from the Guangdong Experimental Animal Center. The study complied with the Canadian Council on Animal Care guidelines and the Guide for the Care and Use of Laboratory Animals. The mice were randomly assigned to five groups, each consisting of ten animals. The normal control group and the model group received normal saline, while the three DCP groups received intragastric administration of the polysaccharide at doses of 50, 100, or 200 mg per kilogram per day for seven days. On the eighth day, the drinking water for the model and DCP groups was replaced with a 2.7% DSS solution to induce the IBD model. This modeling cycle lasted seven days, during which the gavage treatment continued. The experimental protocol included a 12-hour fasting period before tissue collection, ensuring standardized conditions for the subsequent analysis of colon tissue and cecal contents.

The analysis of the gut microbiome revealed specific shifts in dominant flora at various taxonomic levels. At the class level, the model group showed a significant decrease in the relative abundances of Clostridia, Erysipelotrichia, and Bacilli, while Bacteroidia increased significantly. DCP intervention reversed these trends, increasing the former and decreasing the latter. At the order level, Clostridiales decreased and Bacteroidales increased in the model group, with DCP treatment restoring Clostridiales and reducing Bacteroidales. At the family level, Bacteroidaceae and Muribaculaceae were significantly increased in the model group, while Erysipelotrichaceae decreased. DCP intervention significantly reduced the abundances of Bacteroidaceae and Muribaculaceae and increased Erysipelothrix.

Metabolomic analysis using Principal Component Analysis and Partial Least Squares Discriminant Analysis further characterized the differences between the groups. The PCA score chart indicated that the composition of feces within the same group was similar, with PCA1 accounting for 61.8% and PCA2 for 22.2% of the variance. The PLS-DA model demonstrated high predictive power, with an R2X cumulative value greater than 0.5. A permutation test confirmed the accuracy of the model, with a Q2 value less than 0 indicating that the model was not overfitted. These statistical validations support the reliability of the observed differences in metabolite profiles between the control, model, and DCP medium-dose groups.

The authors acknowledged that the current research on the improvement of IBD activity by DCP is not yet comprehensive. The study was limited to in vivo exploration in mice, and the authors expressed the hope that future research would be more in-depth and comprehensive. They noted that the point of view analysis in this study was not thorough enough and that further investigation is needed to fully understand the mechanisms of action. The team plans to conduct more preparations and activity exploration experiments on the effect of DCP on improving inflammatory bowel disease. This ongoing work aims to provide references for the further development and application of Dendrobium and its polysaccharide components.

Subject of Research: The effect of Dendrobium chrysotoxum polysaccharide on intestinal barrier and microbiota in a mouse model of inflammatory bowel disease

Article Title: Effect and mechanism of Dendrobium chrysotoxum polysaccharide on the prevention and treatment of inflammatory bowel disease in mice

Article References: Wu, M., Xia, Z., Hao, Y., Feng, D., Liu, H., Xiao, C., & Liao, W. (2026). Effect and mechanism of Dendrobium chrysotoxum polysaccharide on the prevention and treatment of inflammatory bowel disease in mice. Food, Nutrition and Health, 3(1), Article 1. https://doi.org/10.1007/s44403-025-00031-2

Image Credits: AI Generated

DOI: 10.1007/s44403-025-00031-2

Keywords: inflammatory bowel disease, Dendrobium chrysotoxum, polysaccharide, intestinal barrier, gut microbiota, short-chain fatty acids, mouse model, tight junction proteins, natural medicine, Effect, mechanism, Dendrobium

News Source: Alan Morgan. (November 10, 2026). Dendrobium Polysaccharide Restores Intestinal Barrier in Mice. Scienmag.

Tags: DendrobiumDendrobium chrysotoxumeffectgut microbiotainflammatory bowel diseaseintestinal barriermechanismmouse modelnatural medicinepolysaccharideshort-chain fatty acidstight junction proteins
Share12Tweet7Share2ShareShareShare1

Related Posts

BTN3A3 Downregulation Across Multiple Cancers Points to Potential Metastatic Biomarker

BTN3A3 Downregulation Across Multiple Cancers Points to Potential Metastatic Biomarker

November 17, 2026
Elevated Stress Hyperglycemia Ratio Not Independently Linked to Acute Kidney Injury Risk

Elevated Stress Hyperglycemia Ratio Not Independently Linked to Acute Kidney Injury Risk

November 17, 2026

Targeted Psoriasis Biologics Reshape Immune-Adipose Crosstalk and Suppress Inflammatory Visfatin

November 17, 2026

Wastewater Genomics Detects SARS-CoV-2 Mutations Months Before Clinical Identification

November 17, 2026

POPULAR NEWS

  • Orthognathic Mixed Reality Templates Show Sub-Two-Millimeter Deviations in Early Scoping Review

    Orthognathic Mixed Reality Templates Show Sub-Two-Millimeter Deviations in Early Scoping Review

    29 shares
    Share 12 Tweet 7
  • Iron Oxide Nanoparticles Alleviate Cadmium Stress and Accumulation in Atractylodes Lancea

    29 shares
    Share 12 Tweet 7
  • Elevated Lipoprotein (a) Does Not Predict Long-Term Mortality After Heart Attack

    29 shares
    Share 12 Tweet 7
  • Incremental Deep Learning Reconstruction Improves High-Resolution Coronary CT Angiography Image Quality

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Mirabilis Jalapa Extracts Modulate Optical Band Gap in Polyvinyl Alcohol Films

BTN3A3 Downregulation Across Multiple Cancers Points to Potential Metastatic Biomarker

Affect-Aware Framework May Improve Relational Grounding in LLM Conversations

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.